Clinical Trials Logo

Clinical Trial Summary

To assess the outcome of using magnesium sulphate on fetus and women with preterm premature rupture of membranes


Clinical Trial Description

Preterm premature rupture of membranes (PPROM) is defined as rupture of the chorioamniotic membranes before the onset of labor prior to 37 weeks of gestation. Approximately 1% to 5% of pregnancies are complicated by PPROM . PPROM contributes to perinatal morbidity and mortality, secondary to premature birth, and maternal morbidity. Overall, PPROM accounts for about one-third of all preterm births . In order to reduce the effects of prematurity, early PPROM (24 to 33 weeks) is best served with conservative management in the absence of labor, infection, or fetal distress . The conservative management of PPROM consists of the use of antibiotic treatment and antenatal steroid to enhance fetal lung maturity . With or without the presence of labor, it is unclear whether tocolysis of women with PPROM would be efficacious in reducing the consequences of prematurity .The use of tocolytics in women with PPROM is still controversial. Many physicians use tocolytic therapy as a prophylactic measure and others initiate tocolysis only with the onset of contractions. There is also a variety of options for tocolysis: betamimetics, calcium channel blockers, cyclo-oxygenase (COX) inhibitors, oxytocin receptor antagonists and magnesium sulphate . As betamimetis is not available and isn't used in our country and magnesium sulphate is available magnesium sulphate is used widly. The loading dose of magnesium sulphate is IV 4 gm over 20 minutes followed by 1gm/hour for 6 hours The potential benefit from increased latency due to tocolysis must be weighed against the potential harm in increased maternal and perinatal infection, the latter of which can possibly lead to long-term sequelae for the child, including cerebral palsy ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05134688
Study type Interventional
Source Assiut University
Contact Ahmed Fathi
Phone 01002058742
Email Ahmedalfathi94@gmail.com
Status Not yet recruiting
Phase Early Phase 1
Start date May 30, 2022
Completion date December 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT04100252 - The Impact of Amniotic Fluid Index (AFI) on Maternal and Perinatal Outcomes in Pregnant Women With Preterm Premature Rupture of Membranes
Recruiting NCT04478942 - PROMMO Trial: Oral Misoprostol vs IV Oxytocin Early Phase 1
Recruiting NCT02819570 - Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes Phase 4
Withdrawn NCT03172858 - Randomized Control Trial of Intracervical Balloon Placement vs Oxytocin in Women With Term PROM and Unripe Cervices N/A
Not yet recruiting NCT03689062 - Premature Rupture of Membranes at 34 to 37 Weeks' Gestation N/A
Recruiting NCT06273891 - Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes Phase 3
Recruiting NCT04237142 - Preterm Premature Rupture of Fetal Membranes: Cervical Ultrasound and Biological Markers to Diagnose Prematurity (RECHOBIOL) N/A
Recruiting NCT04558996 - Spanish Registry of Pregnant Women With COVID-19
Recruiting NCT04632017 - Computerized Cardiotocography Monitoring of Fetuses With pPROM
Recruiting NCT03607929 - HIDRATA Study: Efficacy of a Hydration Protocol in Nulliparous Women During Labor N/A
Completed NCT03491826 - Fetal and Maternal Outcome in Preterm Premature Rupture of Membranes (PPROM)
Enrolling by invitation NCT04451109 - Dilapan-S®: A Multicenter US E-registry
Recruiting NCT04143685 - Labor Induction With Misoprostol Versus Oxytocin in Women With Premature Rupture of Membranes N/A
Completed NCT03251898 - Correlation Between Premature Rupture of Membranes and Early-onset Neonatal Infections
Completed NCT03106311 - The Use of Quantitative Pregnancy Test in Amniotic Fluid as a Diagnostic Tool for Rupture of Fetal Membranes N/A